|
| 36136304 | Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. | Clin Cancer Res | 2023 |
| 37915024 | Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. | Mol Cancer | 2023 |
| 37653397 | Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. | Breast Cancer Res | 2023 |
| 37788341 | Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. | Mol Cancer Ther | 2023 |
| 37219486 | Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity. | FASEB J | 2023 |
| 37275963 | Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclibâ¿¿+â¿¿endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2- early breast cancer. | Ther Adv Med Oncol | 2023 |
| 36884217 | Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. | Clin Cancer Res | 2023 |
| 36921335 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. | J Clin Oncol | 2023 |
| 36881998 | Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. | J Clin Oncol | 2023 |
| 36709663 | Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. | Gynecol Oncol | 2023 |
| 36631725 | Tumor biomarkers and efficacy in patients treated with trastuzumab emtansineâ¿¿+â¿¿pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). | Breast Cancer Res | 2023 |
| 36564285 | Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. | Ann Oncol | 2023 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35110416 | Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. | Clin Cancer Res | 2022 |
| 35417017 | Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. | Mol Cancer Ther | 2022 |
| 35552673 | Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. | Clin Cancer Res | 2022 |
| 36291835 | Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. | Cancers (Basel) | 2022 |
| 35917168 | Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. | Oncologist | 2022 |
| 34954044 | Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. | Ann Oncol | 2022 |
| 34980598 | Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. | Clin Cancer Res | 2022 |
| 33369581 | Frontiers in HER2-positive breast cancer in 2020. | Curr Opin Obstet Gynecol | 2021 |
| 34966897 | Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. | Nat Cancer | 2021 |
| 34470810 | Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. | Clin Cancer Res | 2021 |
| 34381210 | Cycling cancer persister cells arise from lineages with distinct programs. | Nature | 2021 |
| 34642026 | Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. | Gynecol Oncol | 2021 |
| 34625570 | A careful reassessment of anthracycline use in curable breast cancer. | NPJ Breast Cancer | 2021 |
| 34102253 | Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. | Ann Oncol | 2021 |
| 33951110 | Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. | PLoS One | 2021 |
| 33229045 | Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. | Gynecol Oncol | 2021 |
| 31448513 | Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. | Breast J | 2020 |
| 31825569 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. | N Engl J Med | 2020 |
| 33157050 | Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. | Cancer Cell | 2020 |
| 33203854 | Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). | Nat Commun | 2020 |
| 32683565 | Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). | Breast Cancer Res Treat | 2020 |
| 32795346 | Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. | Breast Cancer Res | 2020 |
| 32783178 | Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. | Breast Cancer Res Treat | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 31615937 | Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer. | Clin Cancer Res | 2020 |
| 31527167 | Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. | Clin Cancer Res | 2020 |
| 30573544 | Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis. | Science | 2019 |
| 30032196 | Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. | J Natl Cancer Inst | 2019 |
| 31446981 | Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. | Lung Cancer | 2019 |
| 31303643 | Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. | Br J Cancer | 2019 |
| 31157583 | Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. | J Clin Oncol | 2019 |
| 30868391 | Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. | Breast Cancer Res Treat | 2019 |
| 31097597 | Role for polo-like kinase 4 in mediation of cytokinesis. | Proc Natl Acad Sci U S A | 2019 |
| 30709633 | Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. | Lancet Oncol | 2019 |
| 30962322 | Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. | Mol Cancer Ther | 2019 |
| 30632023 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. | Breast Cancer Res Treat | 2019 |